References
- QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
- WebersCABeckersHJNuijtsRMSchoutenJSPharmacological management of primary open-angle glaucoma: second-line options and beyondDrugs Aging200825972975918729546
- KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol2002120670171312049574
- DjafariFLeskMRHarasymowyczPJDesjardinsDLachaineJDeterminants of adherence to glaucoma medical therapy in a long-term patient populationJ Glaucoma200918323824319295380
- HigginbothamEJConsiderations in glaucoma therapy: fixed combinations versus their component medicationsClin Ophthalmol201041920169043
- SallKThe efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study GroupSurv Ophthalmol200044Suppl 2S155S16210665518
- BoyleJEGhoshKGieserDKAdamsonsIAA randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study GroupOphthalmology199810510194519519787368
- KabackMScoperSVArzenoGIntraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%Ophthalmology2008115101728173418538406
- MichaudJEFrirenBInternational Brinzolamide Adjunctive Study GroupComparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertensionAm J Ophthalmol2001132223524311476685
- BarnebeyHKwokSYPatients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice settingClin Ther200022101204121211110231
- SilverLHOcular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study GroupSurv Ophthalmol200044Suppl 2S141S14510665516
- DreerLEGirkinCMansbergerSLDeterminants of medication adherence to topical glaucoma therapyJ Glaucoma201221423424021623223
- MundorfTKRauchmanSHWilliamsRDNotivolRBrinzolamide/Timolol Preference Study GroupA patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertensionClin Ophthalmol20082362362819668763
- SanseauASampaolesiJSuzukiERJrLopesJFBorelHPreference for a fixed combination of brinzolamide/timolol versus dorzolamide/timolol among patients with open-angle glaucoma or ocular hypertensionClin Ophthalmol2013735736223440904
- OkekeCOQuigleyHAJampelHDAdherence with topical glaucoma medication monitored electronically: the Travatan Dosing Aid studyOphthalmology2009116219119919084273
- SleathBRobinALCovertDPatient-reported behavior and problems in using glaucoma medicationsOphthalmology2006113343143616458967
- LanzlIRaberTEfficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practiceClin Ophthalmol2011529129821468336
- VoldSDEvansRMStewartRHWaltersTMallickSA one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertensionJ Ocul Pharmacol Ther200824660160519049301
- AugerGARaynorMLongstaffSPatient perspectives when switching from Cosopt® (dorzolamide-timolol) to Azarga™ (brinzolamide-timolol) for glaucoma requiring multiple drug therapyClin Ophthalmol201262059206223271886
- ManniGDenisPChewPThe safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertensionJ Glaucoma200918429330019365194